Cyteir Therapeutics Performance
| CYTDelisted Stock | USD 2.76 0.01 0.36% |
The firm shows a Beta (market volatility) of 0.67, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cyteir Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cyteir Therapeutics is expected to be smaller as well. Cyteir Therapeutics right now shows a risk of 0.0%. Please confirm Cyteir Therapeutics potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Cyteir Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cyteir Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Cyteir Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 154.1 M | |
| Free Cash Flow | -25.8 M |
Cyteir |
Cyteir Therapeutics Relative Risk vs. Return Landscape
If you would invest 276.00 in Cyteir Therapeutics on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Cyteir Therapeutics or generate 0.0% return on investment over 90 days. Cyteir Therapeutics is generating negative expected returns assuming volatility of 0.0% on return distribution over 90 days investment horizon. In other words, 0% of stocks are less volatile than Cyteir, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Cyteir Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyteir Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cyteir Therapeutics, and traders can use it to determine the average amount a Cyteir Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CYT |
Based on monthly moving average Cyteir Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyteir Therapeutics by adding Cyteir Therapeutics to a well-diversified portfolio.
Cyteir Therapeutics Fundamentals Growth
Cyteir Stock prices reflect investors' perceptions of the future prospects and financial health of Cyteir Therapeutics, and Cyteir Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cyteir Stock performance.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (20.89 M) | |||
| Shares Outstanding | 36 M | |||
| Price To Earning | 0.36 X | |||
| Price To Book | 0.87 X | |||
| EBITDA | (33.41 M) | |||
| Cash And Equivalents | 166.4 M | |||
| Cash Per Share | 4.71 X | |||
| Total Debt | 889 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 3.47 X | |||
| Cash Flow From Operations | (25.79 M) | |||
| Earnings Per Share | (0.93) X | |||
| Total Asset | 153.23 M | |||
| Retained Earnings | (138.11 M) | |||
| Current Asset | 834.8 M | |||
| Current Liabilities | 366.9 M | |||
About Cyteir Therapeutics Performance
Assessing Cyteir Therapeutics' fundamental ratios provides investors with valuable insights into Cyteir Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cyteir Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company was incorporated in 2012 and is based in Lexington, Massachusetts. Cyteir Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people.Things to note about Cyteir Therapeutics performance evaluation
Checking the ongoing alerts about Cyteir Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cyteir Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cyteir Therapeutics is not yet fully synchronised with the market data | |
| Cyteir Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (33.22 M) with loss before taxes, overhead, and interest of (16.59 M). | |
| Cyteir Therapeutics has about 166.4 M in cash with (25.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 77.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Cyteir Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cyteir Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cyteir Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cyteir Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cyteir Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cyteir Therapeutics' stock. These opinions can provide insight into Cyteir Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |